LPIN1

Summary

LPIN1 (lipin 1, HGNC:13345) is a protein-coding gene on chromosome 2p25.1, encoding Phosphatidate phosphatase LPIN1 (Q14693). Acts as a magnesium-dependent phosphatidate phosphatase enzyme which catalyzes the conversion of phosphatidic acid to diacylglycerol during triglyceride, phosphatidylcholine and phosphatidylethanolamine biosynthesis and therefore controls the metabolism of fatty acids at differe….

This gene encodes a magnesium-ion-dependent phosphatidic acid phosphohydrolase enzyme that catalyzes the penultimate step in triglyceride synthesis including the dephosphorylation of phosphatidic acid to yield diacylglycerol. Expression of this gene is required for adipocyte differentiation and it also functions as a nuclear transcriptional coactivator with some peroxisome proliferator-activated receptors to modulate expression of other genes involved in lipid metabolism. Mutations in this gene are associated with metabolic syndrome, type 2 diabetes, acute recurrent rhabdomyolysis, and autosomal recessive acute recurrent myoglobinuria (ARARM). This gene is also a candidate for several human lipodystrophy syndromes.

Source: NCBI Gene 23175 — RefSeq curated summary.

At a glance

• Gene–disease (curated): myoglobinuria, acute recurrent, autosomal recessive (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 4
• Clinical variants (ClinVar): 818 total — 35 pathogenic, 17 likely-pathogenic
• Phenotypes (HPO): 41
• MANE Select transcript: NM_001349206

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13345
Approved symbol	LPIN1
Name	lipin 1
Location	2p25.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0188
Ensembl gene	ENSG00000134324
Ensembl biotype	protein_coding
OMIM	605518
Entrez	23175

Gene structure

Transcript identifiers

Ensembl transcripts: 49 — 38 protein_coding, 6 protein_coding_CDS_not_defined, 4 retained_intron, 1 nonsense_mediated_decay

ENST00000256720, ENST00000396097, ENST00000396098, ENST00000396099, ENST00000404113, ENST00000423495, ENST00000425416, ENST00000441684, ENST00000449576, ENST00000454151, ENST00000460096, ENST00000464517, ENST00000464953, ENST00000475286, ENST00000475922, ENST00000480315, ENST00000487346, ENST00000487576, ENST00000495907, ENST00000674199, ENST00000852426, ENST00000852427, ENST00000852428, ENST00000852429, ENST00000852430, ENST00000852431, ENST00000852432, ENST00000852433, ENST00000852434, ENST00000852435, ENST00000852436, ENST00000852437, ENST00000852438, ENST00000852439, ENST00000852440, ENST00000852441, ENST00000852442, ENST00000914304, ENST00000961822, ENST00000961823, ENST00000961824, ENST00000961825, ENST00000961826, ENST00000961827, ENST00000961828, ENST00000961829, ENST00000961830, ENST00000961831, ENST00000961832

RefSeq mRNA: 13 — MANE Select: NM_001349206 NM_001261427, NM_001261428, NM_001349199, NM_001349200, NM_001349201, NM_001349202, NM_001349203, NM_001349204, NM_001349205, NM_001349206, NM_001349207, NM_001349208, NM_145693

CCDS: CCDS1682, CCDS58699, CCDS58701, CCDS92716

Canonical transcript exons

ENST00000674199 — 21 exons

Exon	Start	End
ENSE00001523901	11776086	11776193
ENSE00001613708	11784886	11785076
ENSE00001745152	11783829	11783922
ENSE00001749441	11771372	11771679
ENSE00001752066	11782201	11782507
ENSE00001787958	11773620	11773745
ENSE00001791157	11787074	11787167
ENSE00001825961	11824632	11827409
ENSE00003482734	11765533	11765733
ENSE00003544937	11779519	11779645
ENSE00003547219	11788387	11788456
ENSE00003554206	11820411	11820514
ENSE00003714286	11815088	11815240
ENSE00003734815	11795408	11795487
ENSE00003739202	11791914	11792006
ENSE00003741060	11819484	11819598
ENSE00003742076	11802907	11803033
ENSE00003751824	11805070	11805156
ENSE00003752351	11804423	11804571
ENSE00003788441	11767763	11767858
ENSE00003898379	11746632	11746671

Expression profiles

Bgee: expression breadth ubiquitous, 297 present calls, max score 99.91.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.4436 / max 258.5051, expressed in 1815 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
18914	23.7097	1813
18915	3.0108	954
18909	0.3268	81
18908	0.2391	77
18917	0.0824	30
18913	0.0398	3
18912	0.0350	3

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	99.91	gold quality
male germ cell	CL:0000015	99.44	gold quality
lower esophagus mucosa	UBERON:0035834	98.32	gold quality
olfactory bulb	UBERON:0002264	98.31	gold quality
buccal mucosa cell	CL:0002336	98.20	gold quality
trigeminal ganglion	UBERON:0001675	98.15	gold quality
sural nerve	UBERON:0015488	97.97	gold quality
gastrocnemius	UBERON:0001388	97.81	gold quality
dorsal root ganglion	UBERON:0000044	97.74	gold quality
tibial nerve	UBERON:0001323	97.47	gold quality
right testis	UBERON:0004534	97.23	gold quality
muscle of leg	UBERON:0001383	97.21	gold quality
esophagus squamous epithelium	UBERON:0006920	97.18	gold quality
left testis	UBERON:0004533	96.94	gold quality
muscle organ	UBERON:0001630	96.93	gold quality
skeletal muscle organ	UBERON:0014892	96.93	gold quality
quadriceps femoris	UBERON:0001377	96.55	gold quality
medial globus pallidus	UBERON:0002477	96.48	gold quality
vastus lateralis	UBERON:0001379	96.44	gold quality
deltoid	UBERON:0001476	96.43	gold quality
globus pallidus	UBERON:0001875	96.21	gold quality
inferior olivary complex	UBERON:0002127	96.14	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.09	gold quality
lateral globus pallidus	UBERON:0002476	95.97	gold quality
body of tongue	UBERON:0011876	95.96	gold quality
skeletal muscle tissue	UBERON:0001134	95.82	gold quality
testis	UBERON:0000473	95.56	gold quality
tibialis anterior	UBERON:0001385	95.49	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	95.49	gold quality
superior surface of tongue	UBERON:0007371	95.43	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.68
E-GEOD-100618	no	1354.63
E-CURD-46	no	11.37
E-CURD-112	no	2.76

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF1, CEBPA, CEBPB, CREB3L3, EGR1, ETS2, FOXC1, HIF1A, HNF4A, KDM5D, NFATC4, NFE2L1, NFYA, NFYB, NFYC, NRF1, SREBF1, STAT3

miRNA regulators (miRDB)

100 targeting LPIN1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4533	100.00	69.48	2758
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-106B-5P	99.88	74.72	2795

Literature-anchored findings (GeneRIF, showing 40)

• LPIN1 mutations are not commonly seen in patients with lipodystrophy who had no mutations in known disease genes. (PMID:12111372)
• effects of genetic variation in lipin levels on glucose homeostasis across species by analyzing lipin transcript levels in human and mouse adipose tissues (PMID:16357106)
• human lipin 1 is a Mg2+-dependent PA phosphatase, the penultimate enzyme in the pathway to synthesize triacylglyerol (PMID:16467296)
• Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway (PMID:16950137)
• These results suggest that increased adipogenesis and/or lipogenesis in subcutaneous fat, mediated by the LPIN1 gene, may prevent lipotoxicity in muscle, leading to improved insulin sensitivity (PMID:17003347)
• Body fat accumulation is a major regulator of human adipose LPIN1 expression and suggests a role of LPIN1 in human preadipocyte as well as mature adipocyte function. (PMID:17035674)
• insulin and epinephrine control lipin primarily by changing localization rather than intrinsic PAP activity (PMID:17105729)
• Lipin 1beta and overexpression of peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1alpha are downregulated by obesity and obesity-related metabolic perturbations in human subjects. (PMID:17563064)
• Variants of the LPIN1 gene have significant effects in human metabolic traits and implicate lipin in the pathophysiology of the metabolic syndrome. (PMID:17940119)
• LPIN1 messenger RNA levels positively correlated with insulin sensitivity in all subjects with obesity, NIDDM, and HIV-associated lipodystrophy (PMID:17950103)
• Sequence variation in the LPIN1 gene contributes to variation in resting metabolic rate and obesity-related phenotypes potentially in an age-dependent manner. (PMID:18070763)
• Lpin1 glucocorticoid response element binds to the glucocorticoid receptor (PMID:18362392)
• Study provides further evidence that lipin 1 may play a role in blood pressure regulation, especially in men. (PMID:18437145)
• Our data do not support a major effect of common LPIN1 variation on metabolic traits and suggest that mutations in LPIN1 are not a common cause of lipodystrophy in humans (PMID:18591397)
• LPIN1 genetic variations can affect rosiglitazone treatment response in T2DM. (PMID:18693052)
• distinct and non-redundant functions of lipin 1 and 2 regulate lipid production during the cell cycle and adipocyte differentiation (PMID:18694939)
• Mutations in the LPIN1 gene cause recurrent rhabdomyolysis in childhood, and a carrier state may predispose for statin-induced myopathy (PMID:18817903)
• Decreased expression of lipin 1 beta in visceral and subcutaneous adipose tissue appears to contribute to the pathogenesis of insulin resistance in polycystic ovary syndrome. (PMID:18829900)
• the LPIN1 gene seemed not to be a major susceptibility gene for type 2 diabetes or related metabolic phenotypes in the Chinese population. (PMID:19543209)
• sterol-mediated regulation of lipin 1 gene transcription modulates triglyceride accumulation (PMID:19553673)
• A conserved serine residue is required for the phosphatidate phosphatase activity but not the transcriptional coactivator functions of lipin-1 and lipin-2. (PMID:19717560)
• sumoylation facilitates the nuclear localization and transcriptional coactivator behavior of lipin-1alpha, which may act as a sumoylation-regulated transcriptional coactivator in brain (PMID:19753306)
• Results showed a marked association between LPIN1 and PPARalpha gene expression both in subcutaneous and visceral adipose tissues and might suggest a possible role of LPIN1 in stress conditions that occur in chronic obesity and underlie insulin resistance (PMID:20101248)
• LPIN1 rs33997857, rs6744682, and rs6708316 did not associate with type 2 diabetes, obesity, or related quantitative metabolic phenotypes in the Danish population examined. (PMID:20356931)
• the low-grade proinflammatory environment and the insulin resistance associated with obesity may contribute to downregulate LPIN1 in adipose tissue (PMID:20530740)
• Data suggest that the high frequency of the intragenic LPIN1 deletion should provide a valuable criterion for fast diagnosis, prior to muscle biopsy. (PMID:20583302)
• Data revealed that lipin 1 formed stable homo-oligomers with itself and hetero-oligomers with lipin 2/3. (PMID:20735359)
• PPARG and LPIN1 gene polymorphisms role of these genes in lipid metabolism and pathogenesis of type 2 diabetes and metabolic syndrome (PMID:21263402)
• dullard shows specificity for the peptide corresponding to the insulin-dependent phosphorylation site (Ser106) of lipin (PMID:21413788)
• The aim of present study was to investigate for the first time the association of lipin 1 gene polymorphisms with metabolic and hormonal profile in polycystic ovary syndrome patients and controls. (PMID:21448847)
• data suggest that lipin-1 associates with lipid droplets and regulates the activation of cytosolic group IVA phospholipase A(2)alpha in monocyte-derived macrophages (PMID:21478406)
• lipin-1gamma is the main lipin-1 isoform expressed in normal human brain, suggesting a specialized role in regulating brain lipid metabolism. (PMID:21616074)
• reduced expression of SFRS10, as observed in tissues from obese humans, alters LPIN1 splicing, induces lipogenesis, and therefore contributes to metabolic phenotypes associated with obesity. (PMID:21803291)
• Estrogen-related receptor gamma (ERRgamma) is a novel transcriptional regulator of phosphatidic acid phosphatase, LIPIN1, and inhibits hepatic insulin signaling (PMID:21911493)
• Lpin1 expression in response to nutritional stress is controlled through the reactive oxygen species-ATM-p53 pathway. (PMID:22055193)
• Lipin1 rs13412852 single nucleotide polymorphism is associated with the severity of liver damage and fibrosis progression in pediatric patients with histological NAFLD. (PMID:22157924)
• We conclude that direct control of lipin 1 transcription by HIF-1 is an important regulatory feature of lipid metabolism and its adaptation to hypoxia. (PMID:22467849)
• LPIN1 mutations should be considered in any child presenting with severe rhabdomyolysis. (PMID:22480698)
• LPIN1-related myolysis constitutes a major cause of early-onset rhabdomyolysis and occasionally in adults. Heterozygous LPIN1 mutations may cause mild muscular symptoms. No major defects of LPIN2 or LPIN3 genes were associated with muscle manifestations. (PMID:22481384)
• Data suggests common single nucleotide polymorphisms within the LPIN1 region were associated with Type 2 diabetes and metabolic traits in the Chinese population. (PMID:22853689)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	lpin1a	ENSDARG00000020239
danio_rerio	lpin1b	ENSDARG00000103380
mus_musculus	Lpin1	ENSMUSG00000020593
rattus_norvegicus	Lpin1	ENSRNOG00000004377
drosophila_melanogaster	Lpin	FBGN0263593
caenorhabditis_elegans		WBGENE00010425

Paralogs (3): LPIN2 (ENSG00000101577), LPIN3 (ENSG00000132793), AP5Z1 (ENSG00000242802)

Protein

Protein identifiers

Phosphatidate phosphatase LPIN1 — Q14693 (reviewed: Q14693)

Alternative names: Lipin-1

All UniProt accessions (5): A0A0A0MS66, C9IYP2, C9J278, Q14693, H7C3T1

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a magnesium-dependent phosphatidate phosphatase enzyme which catalyzes the conversion of phosphatidic acid to diacylglycerol during triglyceride, phosphatidylcholine and phosphatidylethanolamine biosynthesis and therefore controls the metabolism of fatty acids at different levels. Is involved in adipocyte differentiation. Recruited at the mitochondrion outer membrane and is involved in mitochondrial fission by converting phosphatidic acid to diacylglycerol. Acts also as nuclear transcriptional coactivator for PPARGC1A/PPARA regulatory pathway to modulate lipid metabolism gene expression.

Subunit / interactions. Interacts (via LXXIL motif) with PPARA. Interacts with PPARGC1A. Interaction with PPARA and PPARGC1A leads to the formation of a complex that modulates gene transcription. Interacts with MEF2C.

Subcellular location. Cytoplasm. Cytosol. Endoplasmic reticulum membrane. Nucleus membrane.

Tissue specificity. Specifically expressed in skeletal muscle. Also abundant in adipose tissue. Lower levels in some portions of the digestive tract.

Post-translational modifications. Phosphorylated at multiple sites by mTOR in response to insulin, leading to its inactivation. Phosphorylation does not affect the catalytic activity but regulates the localization. Phosphorylation is decreased by epinephrine. Dephosphorylated by the CTDNEP1-CNEP1R1 complex. Dephosphorylation following mTOR inhibition promotes its activity. Acetylation at Lys-425 and Lys-595 by KAT5 in response to fatty acids promotes translocation to the endoplasmic reticulum and synthesis of diacylglycerol. Sumoylated.

Disease relevance. Myoglobinuria, acute recurrent, autosomal recessive (ARARM) [MIM:268200] Recurrent myoglobinuria is characterized by recurrent attacks of rhabdomyolysis (necrosis or disintegration of skeletal muscle) associated with muscle pain and weakness and followed by excretion of myoglobin in the urine. Renal failure may occasionally occur. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Potently inhibited by sphingolipids, in particular, the sphingoid bases sphinganine and sphingosine and ceramide-1-phosphate. Inhibited by concentrations of Mg(2+) and Mn(2+) above their optimums and by Ca(2+), Zn(2+), N-ethylmaleimide and propranolol. Sertraline and propanolol inhibit activity in dose-dependent manners with IC(50) values of 103 uM and 226 uM, respectively. Sertraline and propanolol inhibit activity in dose-dependent manners with IC(50) values of 108 uM and 271 uM, respectively. Sertraline and propanolol inhibit activity in dose-dependent manners with IC(50) values of 143 uM and 227 uM, respectively.

Cofactor. Mg(2+) and, at a lesser extent, Mn(2+).

Domain organisation. Contains one Leu-Xaa-Xaa-Ile-Leu (LXXIL), a transcriptional binding motif, which mediates interaction with PPARA. Contains 1 Asp-Xaa-Asp-Xaa-Thr (DXDXT) motif, a catalytic motif essential for phosphatidate phosphatase activity.

Miscellaneous. May represent a candidate gene for human lipodysytropy syndromes.

Similarity. Belongs to the lipin family.

Isoforms (7)

UniProt ID	Names	Canonical?
Q14693-1	1, Alpha	yes
Q14693-2	2
Q14693-3	3, Beta
Q14693-4	4, Gamma
Q14693-5	5
Q14693-6	6
Q14693-7	7

RefSeq proteins (13): NP_001248356, NP_001248357, NP_001336128, NP_001336129, NP_001336130, NP_001336131, NP_001336132, NP_001336133, NP_001336134, NP_001336135, NP_001336136, NP_001336137, NP_663731 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007651	Lipin_N	Domain
IPR013209	LNS2	Domain
IPR026058	LIPIN	Family
IPR031315	LNS2/PITP	Domain
IPR031703	Lipin_mid	Domain
IPR036412	HAD-like_sf	Homologous_superfamily

Pfam: PF04571, PF08235, PF16876

Enzyme classification (BRENDA):

• EC 3.1.3.4 — phosphatidate phosphatase (BRENDA: 31 organisms, 190 substrates, 196 inhibitors, 44 Km, 3 kcat entries)

Substrate kinetics (BRENDA)

10 substrates with measured Km, best-characterized 10. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
PHOSPHATIDIC ACID	0.0054–1.2	17
LYSOPHOSPHATIDATE	0.046–0.179	3
PHOSPHATIDATE	0.284–0.369	3
SPHINGOSINE-1-PHOSPHATE	0.028–0.26	3
CERAMIDE-1-PHOSPHATE	0.022–0.052	2
DIACYLGLYCEROL DIPHOSPHATE	0.041–0.104	2
LYSOPHOSPHATIDIC ACID	0.295–0.58	2
1,2-DIACYL-SN-GLYCEROL-3-PHOSPHATE	0.5954	1
2-(4,4-DIFLUORO-5,7-DIMETHYL-4-BORA-3A,4A-DIAZA-	0.024	1
DIOCTANOYL PHOSPHATIDIC ACID	1.4	1

Catalyzed reactions (Rhea), 12 shown:

• a 1,2-diacyl-sn-glycero-3-phosphate + H2O = a 1,2-diacyl-sn-glycerol + phosphate (RHEA:27429)
• 1,2-dioctadecanoyl-sn-glycero-3-phosphate + H2O = 1,2-dioctadecanoyl-sn-glycerol + phosphate (RHEA:33335)
• 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycerol + phosphate (RHEA:41255)
• 1,2-dihexadecanoyl-sn-glycero-3-phosphate + H2O = 1,2-dihexadecanoyl-sn-glycerol + phosphate (RHEA:43236)
• 1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate + H2O = 1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycerol + phosphate (RHEA:43240)
• 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1,2-di-(9Z-octadecenoyl)-sn-glycerol + phosphate (RHEA:43244)
• 1,2-di-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphate + H2O = 1,2-di-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycerol + phosphate (RHEA:43248)
• 1,2-di-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphate + H2O = 1,2-di-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycerol + phosphate (RHEA:43252)
• 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate + H2O = 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycerol + phosphate (RHEA:43256)
• 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphate + H2O = 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol + phosphate (RHEA:43260)
• 1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphate + H2O = 1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycerol + phosphate (RHEA:43280)
• 1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycerol + phosphate (RHEA:43284)

UniProt features (53 total): modified residue 16, region of interest 7, compositionally biased region 7, splice variant 6, sequence conflict 5, sequence variant 4, short sequence motif 3, cross-link 2, mutagenesis site 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14693-F1	60.88	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (18): 106, 150, 252, 254, 260, 264, 294, 425, 434, 438, 449, 595, 600, 601, 887, 889, 565, 595

Mutagenesis-validated functional residues (2):

Position	Phenotype
425	decreased acetylation by kat5.
595	decreased acetylation by kat5.

Function

Pathways and Gene Ontology

Reactome pathways

20 pathways

ID	Pathway
R-HSA-1483191	Synthesis of PC
R-HSA-1483213	Synthesis of PE
R-HSA-4419969	Depolymerization of the Nuclear Lamina
R-HSA-75109	Triglyceride biosynthesis
R-HSA-9841922	MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
R-HSA-1430728	Metabolism
R-HSA-1483206	Glycerophospholipid biosynthesis
R-HSA-1483257	Phospholipid metabolism
R-HSA-1640170	Cell Cycle
R-HSA-212165	Epigenetic regulation of gene expression
R-HSA-2980766	Nuclear Envelope Breakdown
R-HSA-556833	Metabolism of lipids
R-HSA-68875	Mitotic Prophase
R-HSA-68886	M Phase
R-HSA-69278	Cell Cycle, Mitotic
R-HSA-74160	Gene expression (Transcription)
R-HSA-8979227	Triglyceride metabolism
R-HSA-9818564	Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
R-HSA-9851695	Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes
R-HSA-9917777	Epigenetic regulation by WDR5-containing histone modifying complexes

MSigDB gene sets: 488 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_FATTY_ACID_CATABOLIC_PROCESS, chr2p25, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_NEGATIVE_REGULATION_OF_LIPID_METABOLIC_PROCESS, GOBP_MEMBRANE_DISASSEMBLY, GOLDRATH_IMMUNE_MEMORY, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, GOBP_NEGATIVE_REGULATION_OF_NERVOUS_SYSTEM_PROCESS

GO Biological Process (14): triglyceride mobilization (GO:0006642), mitotic nuclear membrane disassembly (GO:0007077), fatty acid catabolic process (GO:0009062), triglyceride biosynthetic process (GO:0019432), animal organ regeneration (GO:0031100), negative regulation of myelination (GO:0031642), cellular response to insulin stimulus (GO:0032869), positive regulation of transcription by RNA polymerase II (GO:0045944), phosphatidylethanolamine metabolic process (GO:0046337), phosphatidic acid metabolic process (GO:0046473), positive regulation of cold-induced thermogenesis (GO:0120162), negative regulation of phosphatidic acid biosynthetic process (GO:1905694), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631)

GO Molecular Function (4): transcription coactivator activity (GO:0003713), phosphatidate phosphatase activity (GO:0008195), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (10): nucleus (GO:0005634), nuclear envelope (GO:0005635), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), mitochondrial outer membrane (GO:0005741), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), cytosol (GO:0005829), nuclear membrane (GO:0031965), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-15 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	2
Metabolism of lipids	2
Nuclear Envelope Breakdown	1
Triglyceride metabolism	1
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	1
Phospholipid metabolism	1
Gene expression (Transcription)	1
Mitotic Prophase	1
Metabolism	1
M Phase	1
Cell Cycle, Mitotic	1
Cell Cycle	1
Epigenetic regulation by WDR5-containing histone modifying complexes	1
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	1
Epigenetic regulation of gene expression	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
triglyceride metabolic process	2
positive regulation of DNA-templated transcription	2
glycerophospholipid metabolic process	2
intracellular membrane-bounded organelle	2
nucleus	2
endomembrane system	2
cytoplasm	2
organelle membrane	2
mitotic cell cycle	1
nuclear membrane disassembly	1
mitotic cell cycle process	1
fatty acid metabolic process	1
lipid catabolic process	1
monocarboxylic acid catabolic process	1
acylglycerol biosynthetic process	1
regeneration	1
animal organ development	1
regulation of myelination	1
negative regulation of nervous system process	1
myelination	1
negative regulation of cellular process	1
response to insulin	1
cellular response to peptide hormone stimulus	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of multicellular organismal process	1
cold-induced thermogenesis	1
regulation of cold-induced thermogenesis	1
phosphatidic acid biosynthetic process	1
negative regulation of phospholipid biosynthetic process	1
regulation of phosphatidic acid biosynthetic process	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1
transcription coregulator activity	1
lipid phosphatase activity	1
binding	1
catalytic activity	1
organelle envelope	1

Protein interactions and networks

STRING

1852 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LPIN1	PPARA	Q07869	964
LPIN1	PPARGC1A	Q9UBK2	947
LPIN1	PPARG	P37231	909
LPIN1	PLPP2	O43688	856
LPIN1	SREBF1	P36956	829
LPIN1	AGPAT2	O15120	804
LPIN1	HNF4A	P41235	740
LPIN1	PLPP3	O14495	726
LPIN1	BSCL2	Q96G97	713
LPIN1	DGAT1	O75907	708
LPIN1	CTDNEP1	O95476	688
LPIN1	FASN	P49327	660
LPIN1	GPAM	Q9HCL2	654
LPIN1	DGAT2	Q96PD7	647
LPIN1	ACACA	Q13085	644

IntAct

95 interactions, top by confidence:

A	B	Type	Score
LPIN3	CSNK2A2	psi-mi:“MI:0914”(association)	0.640
YWHAE	RGS12	psi-mi:“MI:0914”(association)	0.610
YWHAE	SRSF10	psi-mi:“MI:0914”(association)	0.560
LPIN1	DBH	psi-mi:“MI:0915”(physical association)	0.560
DR1	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
LPIN1		psi-mi:“MI:0915”(physical association)	0.560
FLNA	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
FOS	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
GATM	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
LPIN1	GFAP	psi-mi:“MI:0915”(physical association)	0.560
GRB2	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
GRN	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
GTF2B	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
HSF1	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
LPIN1	HSPB1	psi-mi:“MI:0915”(physical association)	0.560
SRC	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
LPIN1	WFS1	psi-mi:“MI:0915”(physical association)	0.560
LPIN1	GTF3C3	psi-mi:“MI:0915”(physical association)	0.560
KIF1B	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
LPIN1	ATXN10	psi-mi:“MI:0915”(physical association)	0.560
RNF11	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
PIAS4	LPIN1	psi-mi:“MI:0915”(physical association)	0.560
LPIN1	JPH3	psi-mi:“MI:0915”(physical association)	0.560
HTT	LPIN1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (45): LPIN1 (Affinity Capture-MS), LPIN1 (Affinity Capture-MS), LPIN1 (Affinity Capture-MS), LPIN1 (Affinity Capture-MS), LPIN1 (Affinity Capture-MS), LPIN1 (Affinity Capture-Western), LPIN1 (Reconstituted Complex), BTRC (Affinity Capture-Western), CUL1 (Affinity Capture-Western), CSNK1E (Affinity Capture-Western), LPIN1 (Biochemical Activity), LPIN1 (Affinity Capture-MS), LPIN1 (Affinity Capture-RNA), LPIN1 (Affinity Capture-MS), BTRC (Affinity Capture-Western)

ESM2 similar proteins: A0A078CGE6, A2QHV0, A7KAX9, A7SNN5, A9RVK2, B0XPE7, B5X564, D0Z5N4, F4HYG2, F4I114, F4IRW0, F4J394, F4J6F6, F4JY37, O00444, O13839, O24527, O43065, P0CP71, P13185, P38623, P42858, P50526, Q03407, Q0CL79, Q0WPH8, Q14693, Q19192, Q2KHT3, Q2QAV0, Q4WJI7, Q5B4Z3, Q5R9Z7, Q60DG4, Q6GPD0, Q6H647, Q756Z0, Q75CH3, Q75DK7, Q75QN6

Diamond homologs: P32567, Q14693, Q7TNN8, Q91ZP3, Q92539, Q99PI4, Q99PI5, Q9BQK8, Q9FMN2, Q9SF47, Q9UUJ6

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
CTDNEP1	“up-regulates activity”	LPIN1	dephosphorylation
SRC	“up-regulates activity”	LPIN1	phosphorylation
CHKA	“down-regulates activity”	LPIN1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 52 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
TP53 Regulates Metabolic Genes	5	14.8×	1e-03
G2/M DNA damage checkpoint	5	13.7×	1e-03
Cell Cycle, Mitotic	6	6.6×	7e-03
Cell Cycle	8	6.5×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

818 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	35
Likely pathogenic	17
Uncertain significance	323
Likely benign	293
Benign	83

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1205474	NM_001349206.2(LPIN1):c.181C>T (p.Arg61Ter)	Pathogenic
1323246	NM_001349206.2(LPIN1):c.1564C>T (p.Gln522Ter)	Pathogenic
1357179	NM_001349206.2(LPIN1):c.2380del (p.Ser794fs)	Pathogenic
1371806	NM_001349206.2(LPIN1):c.1582C>T (p.Gln528Ter)	Pathogenic
1456198	NC_000002.11:g.(?11905668)(11955386_?)del	Pathogenic
1459559	NC_000002.11:g.(?11959590)(11959744_?)del	Pathogenic
1951473	NM_001349206.2(LPIN1):c.1784del (p.Gly595fs)	Pathogenic
1967744	NM_001349206.2(LPIN1):c.1237_1238del (p.Lys413fs)	Pathogenic
1970429	NM_001349206.2(LPIN1):c.2151del (p.Thr718fs)	Pathogenic
2066424	NM_001349206.2(LPIN1):c.844C>T (p.Arg282Ter)	Pathogenic
2089945	NM_001349206.2(LPIN1):c.264dup (p.Val89fs)	Pathogenic
2106824	NM_001349206.2(LPIN1):c.2019_2025del (p.Ser673_Leu674insTer)	Pathogenic
2112231	NM_001349206.2(LPIN1):c.2055_2056del (p.Phe685fs)	Pathogenic
2427337	NC_000002.11:g.(?11905668)(11964917_?)del	Pathogenic
2444342	NM_001349206.2(LPIN1):c.1029del (p.Gln344fs)	Pathogenic
280315	NM_001349206.2(LPIN1):c.1363_1364dup (p.Asp455fs)	Pathogenic
2857438	NM_001349206.2(LPIN1):c.78_79del (p.Ser28fs)	Pathogenic
3247590	NC_000002.11:g.(?11943013)(11943179_?)del	Pathogenic
3653808	NM_001349206.2(LPIN1):c.1841_1845del (p.Ala614fs)	Pathogenic
3658701	NM_001349206.2(LPIN1):c.1867C>T (p.Gln623Ter)	Pathogenic
3720300	NM_001349206.2(LPIN1):c.1537G>T (p.Glu513Ter)	Pathogenic
3775683	NM_001349206.2(LPIN1):c.288+2dup	Pathogenic
4080003	NM_001349206.2(LPIN1):c.221_222del (p.Val74fs)	Pathogenic
4281679	NM_001349206.2(LPIN1):c.1520dup (p.Leu508fs)	Pathogenic
4736138	NM_001349206.2(LPIN1):c.283_284insCGCCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCGGCCNNNNNNNNNNAAAAAAAAAAAAAAAGAAACAGATAATG (p.Asn94_Asp95insAlaProAlaSerAlaSerGlnSerAlaGlyIleThrGlyValSerHisArgAlaArgProXaaXaaXaaLysLysLysLysLysGluThrAspAsn)	Pathogenic
4776642	NM_001349206.2(LPIN1):c.227del (p.Leu76fs)	Pathogenic
4781861	NM_001349206.2(LPIN1):c.1735del (p.Arg579fs)	Pathogenic
4910	NM_001349206.2(LPIN1):c.643G>T (p.Glu215Ter)	Pathogenic
4911	NM_001349206.2(LPIN1):c.1270C>T (p.Arg424Ter)	Pathogenic
4912	NM_001349206.2(LPIN1):c.2509C>T (p.Arg837Ter)	Pathogenic

SpliceAI

3422 predictions. Top by Δscore:

Variant	Effect	Δscore
2:11746670:CGGTG:C	donor_loss	1.0000
2:11746671:GGTG:G	donor_loss	1.0000
2:11746672:G:C	donor_loss	1.0000
2:11746672:G:GG	donor_gain	1.0000
2:11746673:T:A	donor_loss	1.0000
2:11765519:T:A	acceptor_gain	1.0000
2:11765531:A:AG	acceptor_gain	1.0000
2:11765532:G:A	acceptor_loss	1.0000
2:11765532:G:GG	acceptor_gain	1.0000
2:11765532:GGTGC:G	acceptor_gain	1.0000
2:11765700:G:GT	donor_gain	1.0000
2:11765700:G:T	donor_gain	1.0000
2:11765731:GTG:G	donor_gain	1.0000
2:11765733:GGT:G	donor_loss	1.0000
2:11765734:GT:G	donor_loss	1.0000
2:11765735:T:G	donor_loss	1.0000
2:11767856:CAGG:C	donor_loss	1.0000
2:11767857:AGGTA:A	donor_loss	1.0000
2:11767858:GGT:G	donor_loss	1.0000
2:11767859:GTAAG:G	donor_loss	1.0000
2:11767860:T:A	donor_loss	1.0000
2:11773618:A:AG	acceptor_gain	1.0000
2:11773618:AGAAC:A	acceptor_loss	1.0000
2:11773619:G:GT	acceptor_gain	1.0000
2:11773619:GA:G	acceptor_gain	1.0000
2:11773619:GAA:G	acceptor_gain	1.0000
2:11773619:GAAC:G	acceptor_gain	1.0000
2:11773619:GAACT:G	acceptor_gain	1.0000
2:11773746:GT:G	donor_loss	1.0000
2:11773747:T:G	donor_loss	1.0000

AlphaMissense

6102 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:11765564:C:A	A8D	1.000
2:11765626:G:T	G29W	1.000
2:11765627:G:A	G29E	1.000
2:11765636:A:T	D32V	1.000
2:11765645:T:A	V35D	1.000
2:11765690:T:A	V50D	1.000
2:11765695:T:C	F52L	1.000
2:11765696:T:C	F52S	1.000
2:11765697:T:A	F52L	1.000
2:11765697:T:G	F52L	1.000
2:11765698:G:T	G53W	1.000
2:11765699:G:A	G53E	1.000
2:11767764:T:A	V65D	1.000
2:11767803:T:A	M78K	1.000
2:11767803:T:C	M78T	1.000
2:11767803:T:G	M78R	1.000
2:11767809:T:C	L80S	1.000
2:11767821:G:A	G84E	1.000
2:11767821:G:T	G84V	1.000
2:11767836:T:A	V89D	1.000
2:11779619:T:A	W275R	1.000
2:11779619:T:C	W275R	1.000
2:11787146:T:C	L505P	1.000
2:11804436:T:C	L640S	1.000
2:11804463:T:C	F649S	1.000
2:11804469:T:A	V651D	1.000
2:11804486:G:C	G657R	1.000
2:11804519:T:A	W668R	1.000
2:11804519:T:C	W668R	1.000
2:11804546:T:C	S677P	1.000

dbSNP variants (sampled 300 via entrez): RS1000045707 (2:11790904 A>G), RS1000067965 (2:11692203 T>C), RS1000104542 (2:11722325 C>T), RS1000109917 (2:11713460 A>C,G), RS1000110810 (2:11800159 C>T), RS1000139371 (2:11792571 C>T), RS1000146025 (2:11794006 A>G), RS1000174446 (2:11788391 T>G), RS1000213018 (2:11713516 C>T), RS1000214672 (2:11826364 T>G), RS1000240689 (2:11701161 T>C), RS1000262702 (2:11676408 C>T), RS1000269600 (2:11765166 C>T), RS1000280319 (2:11783491 GA>G), RS1000288059 (2:11747855 T>C)

Disease associations

OMIM: gene MIM:605518 | disease phenotypes: MIM:268200

GenCC curated gene-disease

Disease	Classification	Inheritance
myoglobinuria, acute recurrent, autosomal recessive	Definitive	Autosomal recessive
hereditary recurrent myoglobinuria	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
myoglobinuria, acute recurrent, autosomal recessive	Definitive	AR

Mondo (2): myoglobinuria, acute recurrent, autosomal recessive (MONDO:0009992), hereditary recurrent myoglobinuria (MONDO:0020504)

Orphanet (1): Genetic recurrent myoglobinuria (Orphanet:99845)

HPO phenotypes

41 total (30 of 41 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000083	Renal insufficiency
HP:0000467	Neck muscle weakness
HP:0001265	Hyporeflexia
HP:0001284	Areflexia
HP:0001288	Gait disturbance
HP:0001315	Reduced tendon reflexes
HP:0001324	Muscle weakness
HP:0001919	Acute kidney injury
HP:0001945	Fever
HP:0002153	Hyperkalemia
HP:0002167	Abnormal speech pattern
HP:0002901	Hypocalcemia
HP:0002905	Hyperphosphatemia
HP:0002910	Elevated circulating hepatic transaminase concentration
HP:0002913	Myoglobinuria
HP:0003236	Elevated circulating creatine kinase concentration
HP:0003326	Myalgia
HP:0003394	Muscle spasm
HP:0003554	Type 2 muscle fiber atrophy
HP:0003558	Viral infection-induced rhabdomyolysis
HP:0003621	Juvenile onset
HP:0003652	Recurrent myoglobinuria
HP:0003738	Exercise-induced myalgia
HP:0005216	Impaired mastication
HP:0005521	Disseminated intravascular coagulation
HP:0007340	Lower limb muscle weakness
HP:0008305	Exercise-induced myoglobinuria
HP:0008942	Acute rhabdomyolysis
HP:0008997	Proximal upper limb muscle weakness

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST006309_3	Post bronchodilator percent predicted FEV1 in smoking	4.000000e-06
GCST007576_18	Chronotype	3.000000e-13
GCST009391_453	Metabolite levels	6.000000e-06
GCST90026414_5	Severe insulin-resistant type 2 diabetes	6.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004314	forced expiratory volume
EFO:0008328	chronotype measurement
EFO:0010521	phosphocreatine measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C564832	Myoglobinuria, Acute Recurrent, Autosomal Recessive (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs10192566	Efficacy	3	rosiglitazone	Diabetes Mellitus;Type 2

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs10192566	LPIN1	3	2.75	1	rosiglitazone

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Lipid phosphate phosphatases

CTD chemical–gene interactions

80 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, affects methylation, decreases expression, affects cotreatment, increases abundance	5
Valproic Acid	affects expression, decreases expression, decreases methylation, increases expression	5
Cyclosporine	increases expression, decreases expression	3
bisphenol A	decreases methylation, increases expression	2
entinostat	decreases expression, affects cotreatment	2
bisphenol S	increases expression	2
Resveratrol	affects cotreatment, decreases expression, decreases degradation, decreases ubiquitination, affects reaction (+2 more)	2
Air Pollutants	affects expression, increases abundance, decreases expression	2
Ethanol	increases expression, affects cotreatment, decreases expression, increases abundance, increases reaction	2
Benzo(a)pyrene	decreases expression, affects methylation	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Aflatoxin B1	affects methylation, decreases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment	2
afuresertib	increases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
uranyl acetate	affects expression	1
lead acetate	decreases expression	1
cobaltous chloride	increases expression	1
potassium chromate(VI)	decreases expression	1
aflatoxin B2	increases methylation	1
cupric chloride	decreases expression	1
toosendanin	decreases expression, decreases reaction	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
epigallocatechin gallate	increases expression	1
avobenzone	increases expression	1
celastrol	increases expression	1
tamibarotene	decreases expression	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	decreases expression, decreases reaction, increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B5KA	HAP1 LPIN1 (-) 2	Cancer cell line	Male
CVCL_D1XE	Abcam A-549 LPIN1 KO	Cancer cell line	Male
CVCL_XQ22	HAP1 LPIN1 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.